Highlights

December 13, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of

Cancer Vaccination Approach Incorporates Immunomic Therapeutics' LAMP-Vax Technology with CMV Technology November 22, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Last week results from a study conducted by investigators

Science and health innovation do not exist in a vacuum. The cultural, social and political climate can indeed have a profound effect on funding priorities, public acceptance of new technologies

June 12, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc., will participate in a BioPharma Dealmakers webcast, sponsored in

May 22, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. (ITI) Senior Vice President of Research and Development Teri Heiland, Ph.D., will present on DNA vaccines

Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)   Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics for use in combination with Immunomic’s investigational

Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™   May 18, 2017 Eastern Standard Time ROCKVILLE, Md. & SAN FRANCISCO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held,

THE REMARKABLE SCIENCE BEHIND LAMP TECHNOLOGY – AND ITS POTENTIAL TO TREAT HUMAN DISEASE   The body’s own immune system is its best defense against everything from allergies to cancer

https://www.fiercepharma.com/sponsored/reprogramming-immune-system-to-fight-cancerhttps://www.fiercepharma.com/sponsored/reprogramming-immune-system- Reprogramming the Immune System To Fight Cancer Sponsored by Immunomic Therapeutics, Inc. Nov 14, 2016 12:00am By Teri Heiland, Ph.D and Bill Watt, Ph.D. Cancer immunotherapy marks a turning

Clouds of pollen emanate from cedar trees in Sagamihara, Kanagawa Prefecture, in 2005. | KYODO LIFESTYLE When pollen attacks! Experts reveal new approaches to combating hay fever BY TOMOKO OTAKE

Please take a look at our very own scientists and executives that were highlighted in BioHive, an online community platform for the Bio health Industry.

TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas") and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., "Immunomic Therapeutics") today announced that the